Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy

Authors: Antoine Buetti-Dinh, Rebecca Jensen, Ran Friedman

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

The smoothened (SMO) receptor is an essential component of the Sonic hedgehog (SHH) signalling, which is associated with the development of skin basal cell carcinoma (BCC). SMO inhibitors are indicated for BCC patients when surgical treatment or radiation therapy are not possible. Unfortunately, SMO inhibitors are not always well tolerated due to severe side effects, and their therapeutical success is limited by resistance mutations.

Methods

We investigated how common are resistance-causing mutations in two genomic databases which are not linked to BCC or other cancers, namely 1000 Genomes and ExAC. To examine the potential for combination therapy or other treatments, we further performed knowledge-based simulations of SHH signalling, in the presence or absence of SMO and PI3K/Akt inhibitors.

Results

The database analysis revealed that of 18 known mutations associated with Vismodegib-resistance, three were identified in the databases. Treatment of individuals carrying such mutations is thus liable to fail a priori. Analysis of the simulations suggested that a combined inhibition of SMO and the PI3K/Akt signalling pathway may provide an effective reduction in tumour proliferation. However, the inhibition dosage of SMO and PI3K/Akt depended on the activity of phosphodiesterases (PDEs). Under high PDEs activities, SMO became the most important control node of the network. By applying PDEs inhibition, the control potential of SMO decreased and PI3K appeared as a significant factor in controlling tumour proliferation.

Conclusions

Our systems biology approach employs knowledge-based computer simulations to help interpret the large amount of data available in public databases, and provides application-oriented solutions for improved cancer resistance treatments.

Available only for authorised users

Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008; 8(10):743–54. https://doi.org/10.1038/nrc2503. PubMed Central: PMC4457317. [PubMed: 18813320].

Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, Bonifas JM, Lam CW, Hynes M, Goddard A, Rosenthal A, Epstein EH, de Sauvage FJ. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998; 391(6662):90–2. https://doi.org/10.1038/34201. PubMed: 9422511.

Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012; 34(10):2039–50. https://doi.org/10.1016/j.clinthera.2012.08.011. PubMed: 23036338.

Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, Peukert S, Miller-Moslin K, Yuan J, Guo R, Matsumoto M, Vattay A, Jiang Y, Tsao J, Sun F, Pferdekamper AC, Dodd S, Tuntland T, Maniara W, Kelleher JF, Yao YM, Warmuth M, Williams J, Dorsch M. Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2010; 1(3):130–4. https://doi.org/10.1021/ml1000307. PubMed Central: PMC4007689. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24900187.

Athar M, Li C, Kim AL, Spiegelman VS, Bickers DR. Sonic hedgehog signaling in Basal cell nevus syndrome. Cancer Res. 2014; 74(18):4967–75. https://doi.org/10.1158/0008-5472.CAN-14-1666. PubMed Central: PMC4167483. PubMed: 25172843.

Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, Licitra L, Pilotti S, Bossi P, Perrone F. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015; 9(2):389–97. https://doi.org/10.1016/j.molonc.2014.09.003. PubMed: 25306392.

Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń LM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015; 525(7570):543–7. https://doi.org/10.1038/nature14898. PubMed Central: PMC4921058. PubMed: 26367798.

Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015; 525(7570):538–42. https://doi.org/10.1038/nature14888. PubMed: 26367796.

Friedman R. Drug resistance in cancer: molecular evolution and compensatory proliferation. Oncotarget. 2016; 7(11):11746–55. https://doi.org/10.18632/oncotarget.7459. PubMed Central: PMC4914245. PubMed: 26909596.

10.

Friedman R. Drug resistance missense mutations in cancer are subject to evolutionary constraints. PLoS ONE. 2013; 8(12):82059. https://doi.org/10.1371/journal.pone.0082059. PubMed Central: PMC3869674. PubMed: 24376513.

11.

Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015; 526(7571):68–74. https://doi.org/10.1038/nature15393. PubMed: 26432245. PubMed Central: PMC4750478.

12.

Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016; 536(7616):285–91. https://doi.org/10.1038/nature19057. PubMed Central: PMC5018207. PubMed: PMC5018207.

13.

Buetti-Dinh A, Pivkin IV, Friedman R. S100A4 and its role in metastasis - computational integration of data on biological networks. Mol Biosyst. 2015; 11(8):2238–46. https://doi.org/10.1039/c5mb00110b. PubMed: 26118552.CrossRefPubMed

14.

Buetti-Dinh A, Pivkin IV, Friedman R. S100A4 and its role in metastasis - simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases. Mol Biosyst. 2015; 11(8):2247–54. https://doi.org/10.1039/c5mb00302d. PubMed: 26057862.

15.

Buetti-Dinh A, O’Hare T, Friedman R. Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS ONE. 2016; 11(9):0163011. https://doi.org/10.1371/journal.pone.0163011. PubMed Central: PMC5036789. PubMed:27669408.

16.

Forbes SA, Beare D, Bindal N, Bamford S, Ward S, Cole CG, Jia M, Kok C, Boutselakis H, De T, Sondka Z, Ponting L, Stefancsik R, Harsha B, Tate J, Dawson E, Thompson S, Jubb H, Campbell PJ. COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer. Curr Protoc Hum Genet. 2016; 91:1–10. https://doi.org/10.1002/cphg.21. PubMed: 27727438.

17.

Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 2008; 18(1):73–9. https://doi.org/10.1016/j.gde.2008.01.004. PubMed: 18325754.

18.

Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R, Hirawat S. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther. 2016; 9:203–10. https://doi.org/10.2147/OTT.S89967. PubMed Central: PMC4708174. PubMed:26793003.

19.

Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos D, Libra M, Tsatsakis AM. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). Int J Oncol. 2016; 48(3):869–85. https://doi.org/10.3892/ijo.2015.3306. PubMed Central: PMC4750533. PubMed: 26698230.

20.

Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br J Pharmacol. 2006; 147 Suppl 1:252–7. https://doi.org/10.1038/sj.bjp.0706495. PubMed Central: PMC1760738. PubMed: 16402111.

21.

Schmidt DT, Watson N, Dent G, Ruhlmann E, Branscheid D, Magnussen H, Rabe KF. The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol. 2000; 131(8):1607–18. https://doi.org/10.1038/sj.bjp.0703725. PubMed Central: PMC1572487. PubMed:11139438.

22.

Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014; 13(4):290–314. https://doi.org/10.1038/nrd4228. PubMed Central: PMC4155750. PubMed: 24687066.

23.

Yamanaka Y, Mammoto T, Kirita T, Mukai M, Mashimo T, Sugimura M, Kishi Y, Nakamura H. Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP. Cancer Lett. 2002; 176(2):143–8. PubMed: 11804741.

24.

Murata K, Kameyama M, Fukui F, Ohigashi H, Hiratsuka M, Sasaki Y, Kabuto T, Mukai M, Mammoto T, Akedo H, Ishikawa O, Imaoka S. Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility. Clin Exp Metastasis. 1999; 17(6):525–30. PubMed: 10763919.

25.

McEwan DG, Brunton VG, Baillie GS, Leslie NR, Houslay MD, Frame MC. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res. 2007; 67(11):5248–57. https://doi.org/10.1158/0008-5472.CAN-07-0097. PubMed: 17545604.

26.

Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res. 2003; 289(2):265–74. PubMed: 14499627.

27.

Kelly K, Mejia A, Suhasini AN, Lin AP, Kuhn J, Karnad AB, Weitman S, Aguiar RC. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. Clin. Cancer Res. 2017; 23(5):1186–92. https://doi.org/10.1158/1078-0432.CCR-16-1207. PubMed Central: PMC5316514. PubMed: 27542768.

28.

Bar-Shavit R, Maoz M, Kancharla A, Nag JK, Agranovich D, Grisaru-Granovsky S, Uziely B. G Protein-Coupled Receptors in Cancer. Int J Mol Sci. 2016; 17(8). PMC5000717. PubMed Central: PMC5000717. PubMed: 27529230.

29.

Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007; 7(2):79–94. https://doi.org/10.1038/nrc2069. PubMed: 17251915.

30.

Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science. 2004; 304(5678):1755–9. https://doi.org/10.1126/science.1098020. PubMed: 15205520.

31.

Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer. 2002; 2(5):361–72. https://doi.org/10.1038/nrc796. PubMed:12044012.

32.

Kasai K, Takahashi M, Osumi N, Sinnarajah S, Takeo T, Ikeda H, Kehrl JH, Itoh G, Arnheiter H. The G12 family of heterotrimeric G proteins and Rho GTPase mediate Sonic hedgehog signalling. Genes Cells. 2004; 9(1):49–58. PubMed: 14723707.

33.

Riobo NA, Saucy B, Dilizio C, Manning DR. Activation of heterotrimeric G proteins by Smoothened. Proc Natl Acad Sci USA. 2006; 103(33):12607–12. https://doi.org/10.1073/pnas.0600880103. PubMed Central: PMC1567926. PubMed: 16885213.

34.

Nusse R. Wnt signaling in disease and in development. Cell Res. 2005; 15(1):28–32. https://doi.org/10.1038/sj.cr.7290260. PubMed: 15686623.

35.

Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691–701. https://doi.org/10.1038/nrg1427. PubMed: 15372092.

36.

Chen W, Ren XR, Nelson CD, Barak LS, Chen JK, Beachy PA, de Sauvage F, Lefkowitz RJ. Activity-dependent internalization of smoothened mediated by beta-arrestin 2 and GRK2. Science. 2004; 306(5705):2257–60. https://doi.org/10.1126/science.1104135. PubMed: 15618519.

Title: A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy
Authors: Antoine Buetti-Dinh
Rebecca Jensen
Ran Friedman
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4451-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

Reconsideration of the optimal minimum lymph node count for young colon cancer patients: a population-based study

Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies

Colorectal cancer survivors: an investigation of symptom burden and influencing factors

MicroRNAs as markers of progression in cervical cancer: a systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer